Product Description:
Primary Objective: Assess minimal disease (MD) or persistent/residual disease (PRD) using pools of primers targeting IgH VH family. Retrospective analysis of specimens from children and adolescents with B-NHL treated with FAB Group B4 therapy (Patte/Cairo et al, Blood, 2007)